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Abstract
Percutaneous coronary intervention (PCI) has evolved into the high-risk category in 
the past 2 decades. Endovascular patients are on average sicker than in the past due to 
increased age, complex anatomy, reduced global left ventricular systolic function and 
a greater frequency of surgical refusal. Extracorporeal membrane oxygenation (ECMO) 
can be taken into account for the management of extremely high-risk PCI without any 
hemodynamic instability. The rationale for the use of ECMO includes a lower risk of 
hemodynamic collapse which leads to low perfusion episodes minimization. In the evi-
dence based on ECMO-assisted high-risk PCI, there are no randomized clinical trials but 
only observational studies and case reports. In this paper, we describe one-year long-
term results of ECMO support for PCI in patients without hemodynamic disturbances.
Keywords: elective high-risk PCI, ECMO, stable angina, acute coronary syndrome
1. Introduction
At present, a clear-cut definition of what is a high-risk percutaneous coronary intervention 
(PCI) is not completely determined. In general, high-risk PCI is an intervention which is likely 
to cause adverse events that will worsen ischemia and reduced cardiac output culminating 
into cardiogenic shock. According to the clinical expert consensus statement [1], variables that 
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contribute to an increased risk of PCI can be classified into three groups: (1) lesion specific 
(Jeopardy Score ≥ 8 [2], calcification, bifurcation, tortuosity, occlusion), (2) clinical presenta-
tion specific (cardiogenic shock, acute coronary syndrome (ACS)), and (3) patient specific 
(age, a history of diabetes mellitus and/or prior myocardial infarction, chronic kidney dis-
ease, ejection fraction <35% on the echocardiography assessment). A different combination of 
these variables can provoke cardiogenic shock in high-risk PCI, whereas the most unfavor-
able option is a combination of severe left ventricular dysfunction (ejection fraction of the left 
ventricle (EF) <35% or recent decompensated heart failure) and a technically complicated PCI 
(left main, last remaining conduit, severe multivessel disease) [1].
In observational studies, extracorporeal membrane oxygenation (ECMO) has an encouraging 
result for PCI in patients with hemodynamic disturbances [3–6]. A meta-analysis or random-
ized clinical trials data are not available for ECMO. That is why current European guidelines 
can only be based on the expert consensus [7–9]: “Short-term mechanical support may be 
considered in patients with refractory shock” (Class of recommendations IIb, level of 
evidence C.)” There is no evidence of the ECMO benefits for PCI in patients with stable angina 
and non–ST-segment elevation acute coronary syndrome (NSTE-ACS) based on long-term 
results data. We are dealing only with single studies presenting hospital outcomes in small 
series of patients and case reports [10–13]. Today, only selected NSTE-ACS patients with car-
diogenic shock are considered for left ventricular assist devices [7]. Approaches implying 
the use of circulatory support devices for patients without hemodynamic disturbances who 
require high-risk PCI are not discussed in the guidelines.
Nowadays, an evolution of PCI to the high-risk category could be observed. Endovascular 
patients are, on average, sicker than in the past due to increased age, complex anatomy, 
severity and extent of coronary artery disease, low left ventricular ejection fraction, co-mor-
bidities (renal failure, cerebrovascular disease, peripheral artery disease, diabetes mellitus 
and chronic obstructive pulmonary disease) and a personal choice of PCI to improve their 
symptoms [1, 14, 15]. Cardiac surgeons are the biggest providers of patients with high-risk 
PCI. Because of an elevated surgical risk (high STS score or EuroScore II) as well as elevated 
ischemic and bleeding risks (in NSTE-ACS patients after P2Y12 inhibitors loading), surgeons 
could refuse coronary artery bypass graft (CABG) interventions [16–19]. Thus, high-risk PCI 
is an appropriate revascularization strategy for patients who are not suitable for surgery or 
have refused CABG.
A patient with co-morbidities and severe stable coronary artery disease (CAD) or NSTE-ACS 
can have a significantly weakened cardiovascular reserve and be more receptive to low myo-
cardial perfusion stunning. At the same time, an aggressive endovascular approach with tech-
nically complex high-risk PCI can be complicated by coronary dissection with vessel closure 
or no reflow or can require longer and balloon inflations with higher pressure. As a result, 
a sequence of adverse events can occur, leading to reduced ejection fraction and increased 
hypoperfusion, resulting in the progression of myocardial ischemia and the development of 
cardiogenic shock and/or multiple organ failures. The rationale for the use of ECMO includes 
a decreased risk of hemodynamic collapse which leads to fewer low perfusion episodes. 
Additionally, a lower risk of hypotensive events could provide an interventional cardiologist 
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with more time to achieve optimal results and complete revascularization. The problem is 
that it is very difficult to take into account all the unfavorable factors, to correctly assess the 
complexity of a particular clinical case and to determine the indications for mechanical circu-
latory support. Having two seemingly comparable patients, we can perform a high-risk PCI 
procedure without adverse outcomes in one case, and with severe hemodynamic disorders in 
the other. To resolve the issue we need to conduct a randomized study in the ECMO support 
PCI versus PCI only but, at the moment, it is not possible due to ethical problems issues and 
a small number of observations.
Currently, a large number of percutaneous mechanical circulatory support devices is avail-
able and has entered clinical practice. These include TandemHeart, intra-aortic balloon pump 
(IABP), ECMO, Impella [1, 14, 15].
ECMO uses a centrifugal pump for artificial circulation of blood. For the purposes of PCI, 
veno-arterial ECMO cannulation approach is selected. There are very little data on the use 
of ECMO in the elective pre-procedural setting: data are limited to reports [12, 13] which 
demonstrated a single-center experience of high-risk PCI with ECMO support as an adjunct 
modality. The conclusion of these reports was that elective pre-PCI ECMO is a viable thera-
peutic alternative capable of ensuring good immediate and mid-term outcomes in high-risk 
CABG patients.
The reason for choosing ECMO support versus other devices for elective high-risk PCI in 
patients without cardiogenic shock is given in our earlier publications [20].
Thus, taking into account a high incidence of chronic CAD and ACS [21] as well as an evolu-
tion of PCI to the high-risk category there is a strong medical and social need to treat these 
patients safely. A number of high-risk PCI patients are considered to be at extremely high 
risk of PCI complications during these complex procedures. Nowadays, the development of 
cardiac support devices such as ECMO has allowed to introduce a safer approach for the 
extremely high-risk patient subset. The extracorporeal membrane oxygenation has some 
advantages over the other types of mechanical circulatory support devices. There is limited 
evidence data on the safety and efficacy of ECMO-assisted high-risk PCI in patients with 
stable CAD and NSTE-ACS. The next parts of this chapter are devoted to analyzing immedi-
ate and long-term outcomes of ECMO support for high-risk PCI without cardiogenic shock as 
an adjunct modality in the elective pre-procedural setting.
2. Immediate and long-term outcomes of ECMO support for complex 
high-risk PCI in stable angina patients: A single-center experience
Elective high-risk PCI with ECMO support in stable angina patients with the multivessel 
disease will be presented in this section. These data are based on the in-hospital and 12-month 
outcomes of a single-center retrospective observational study in the small series of 16 patients. 
The purpose of the study was to evaluate the incidence of MACCE (a composite of all-cause 
death, myocardial infarction (MI), stroke and target vessel revascularization) at 30 days 
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and 12 months. Additionally, bleeding and complete revascularization rates were evalu-
ated. Complete revascularization was defined as the PCI procedure, as a result of which the 
residual SYNTAX score was ≤2. For the classification of bleeding, the definition of Bleeding 
Academic Research Consortium (BARC) was used [22]. Hemorrhagic complications of type 3 
and higher were taken into account.
High-risk PCI was defined as having two of the three parameters [20]: (1) ejection fraction 
<35%; (2) Jeopardy Score ≥ 8 [2]; (3) intervention for bifurcation and/or left main and/or 
chronic total occlusion. An indication for high-risk PCI with ECMO support was based on the 
heart team decision for those patients, who were not suitable for some types of revasculariza-
tion (CABG or PCI) and who had two of the three parameters of high-risk PCI.
We started ECMO prior to PCI and used the “RotaFlow System” (by MAQUET). The ECMO 
cannula was inserted using a surgical technique (9 (56.2%)) and endovascular approach 
(ProStar XL, 7 (45.8%)). The mean ECMO time was 2.4–3.2 L/min/m2 (70–100% from the 
estimated).
The medications during PCI included unfractionated heparin and acetylsalicylic acid. All 
of the patients received the loading dose of clopidogrel before PCI. Aspirin was prescribed 
before revascularization (75 mg once daily) for all the study patients and it was continued 
indefinitely. Unfractionated heparin was used (IV bolus of 100 IU per kilogram of body weight 
followed by an adjustment according to the target activated clotting time of 250–300 seconds). 
Antiplatelet regimen routinely included clopidogrel (a loading dose of 300 mg at the time of 
PCI unless used in advance; then 75 mg daily, the recommended duration of treatment was 
12 months).
Baseline clinical and angiographic characteristics of the study patients are shown in 
Table 1. Of note, the mean age was 62.8 ± 6.5 years, and the majority of patients were 
males (81.2%). Diabetes mellitus was present in 18.7, 75% had a history of myocardial 
infarction, peripheral artery disease was observed in 50% of patients. Left ventricular 
ejection fraction (LVEF) was poor: 37.9 ± 17.5%. Our patients had stenotic lesions of two or 
more significant epicardial arteries and/or large branches (≥2.5 mm) ≥70% and/or stenosis 
of LMCA ≥50%. The target vessel for PCI was determined taking into account the data on 
the viability of the myocardium on cardiac magnetic resonance imaging. Fifteen (93.7%) 
patients had 3 or more affected vessels, significant LMCA stenosis was diagnosed in 7 
(43.7%) patients and mean SYNTAX score was 31.4 ± 9.8. In general, stable CAD patients 
(n = 16) were characterized by a high incidence of a prior MI, very low ejection fraction 
and severe multivessel disease involving LMCA.
We successfully performed all PCI + ECMO interventions. Procedural characteristics and 
in-hospital outcomes of the study patients are shown in Table 2. The mean bypass/PCI 
duration was 115.6 ± 43.7/98.6 ± 31.1 minutes. All of the patients were weaned from the 
system immediately after PCI directly in the cath-lab. Only six (37.5%) patients had a com-
plete revascularization while the mean number/length of implanted stents was 3.6 ± 1.2 
and 75.8 ± 23.4 mm, respectively. Only second-generation drug-eluting stents (DES) were 
implanted. There was one stroke case (6.2%) 5 days after PCI + ECMO which led to the death 
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of the patient with carotid artery disease. A BARC bleeding of type 3 or more was observed 
in 6 (37.5%) patients. The mean hospital stay was 12.6 ± 4.8 days. A significant decrease in 
hemoglobin levels required blood transfusion in six cases. The blood use averaged 4.2 units 
of red blood cells.
Long-term outcomes of the study are presented in Table 2. About 25% mortality rate was 
observed at 12 months. The combined endpoint (all-cause death, myocardial infarction (MI), 
stroke and target vessel revascularization) was observed in 4 (25%) patients. Three (18.7%) 
deaths occurred in the post-hospitalization period as a result of acute myocardial infarc-
tion. Two were due to acute stent thrombosis and one as a consequence of stent restenosis. 
Myocardial infarctions in the long-term follow-up period (3 (18.7%)) were predominantly 
new cases after the hospital discharge and led to TVR in two patients. There were no addi-
tional stroke cases in the follow-up period.
Variables Stable CAD patients
PCI+ ECMO (n = 16)
Mean age 62.8 ± 6.5 (51–75)
Male 13 (81.2%)
Mean left ventricular ejection fraction 37.9 ± 17.5
Left ventricular ejection fraction <35 11 (68.7%)
EuroScore II 3.2 ± 2.4
CCS II 6 (37.5%)
CCS III-IV 10 (62.5%)
Chronic kidney disease 4 (25%)
COPD 2 (12.5%)
Diabetes mellitus 3 (18.7%)
Prior myocardial infarction 12 (75%)
Arterial hypertension 134 (89.3%)
Peripheral artery disease 8 (50%)
Prior stroke 1 (6.2%)
SYNTAX Score 31.4 ± 9.8
Jeopardy score [2] 11.3 ± 0.9
Affected vessels: 1, 2 1 (6.2%)
Affected vessels: ≥3 15 (93.7%)
LMCA stenosis ≥50% 7 (43.7%)
BARC: Bleeding Academic Research Consortium, COPD: chronic obstructive pulmonary disease, CCS: Canadian 
Cardiovascular Society grading of angina pectoris.
Table 1. Baseline characteristics of the study population.
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This study had patients at high risk of adverse events for any type of revascularization (CABG 
and PCI). This is the largest series of consecutive high CABG risk chronic CAD patients who 
underwent ECMO in the elective pre-procedural manner. The main hypothesis of the study 
was that PCI + ECMO may be a feasible strategy of revascularization for stable angina patients 
at a high risk for CABG or PCI only.
All the patients had severe multivessel disease involving LMCA, poor left ventricular fraction 
as a result of a prior MI and underwent challenging PCI with ECMO support as an adjunct 
modality in the elective pre-procedural setting, which allowed to complete a successful revas-
cularization without hemodynamic disturbances and to wean from ECMO immediately after 
PCI. The hospital results looked satisfactory. There were no serious cardiac adverse outcomes. 
Hemorrhagic complications were not fatal, although it is necessary to note a high incidence of 
Variables Stable CAD patients
PCI+ ECMO (n = 16)
In-hospital outcomes
MACCE
• Death
• Stroke
• MI
• TVR
1 (6.2%)
1 (6.2%)
1 (6.2%)
0
0
Mean bypass duration (min) 115.6 ± 43.7
Mean total time of PCI (min) 98.6 ± 31.1
Mean № of stents 3.6 ± 1.2
Mean diameter of stents 3.25 ± 0.5
Mean length of stents (mm) 75.8 ± 23.4
Bleeding (BARC≥3) 6 (37.5%)
Complete revascularization 6 (37.5%)
Residual SYNTAX score 8.5 ± 10.8
Hospital stay (days) 12.6 ± 4.8
12-month outcomes
MACCE
• Death
• Stroke
• MI
• TVR
4 (25%)
4 (25%)
1 (6.2%)
3 (18.7%)
2 (12.5%)
BARC: Bleeding Academic Research Consortium, MI: myocardial infarction, TVR: target vessel revascularization.
Table 2. Procedural characteristics and study end points.
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bleeding and blood transfusions. At the 12-month follow-up, the results became less encour-
aging. A high number of myocardial infarctions in combination with an in-hospital stroke 
led to an increased number of cumulative adverse outcomes of 25%. The attention should 
be drawn to the unsatisfactory effect of implantation of second-generation DES (myocardial 
infarction and death from myocardial infarction in 18.7% of patients). Nevertheless, our data 
do not go beyond the results presented in the literature. The long-term all-cause mortality in 
ischemic cardiomyopathy patients with reduced ejection fraction increased up to 58.9 and 
66.1% in the CABG and guideline-directed medical therapy groups, respectively [23, 24]. The 
main limitation of our analysis is a small number of patients. Therefore, in order to answer 
the question on the role of ECMO for high-risk PCI in chronic CAD patients, larger trials are 
required.
In conclusion, our study was designed to report the unique single-center experience in 
using ECMO to manage high-risk stable angina patients in the catheterization laboratory. 
In-hospital results suggest that PCI with ECMO can be successfully performed and may be 
a feasible strategy of revascularization in a high-risk cohort of chronic CAD patients with 
adverse outcomes after any type of revascularization (CABG and PCI). Bleeding control is a 
critical aspect of care during the PCI + ECMO procedure. The long-term results of PCI with 
the support of artificial circulation require additional evaluation in larger or/and randomized 
studies. Particular attention should be paid to factors that increase the risk of stent thrombosis 
(the number of stents, the quality of stents, the procedure for stent implantation, antiplatelet 
therapy).
3. PCI + ECMO vs. CABG for NSTE-ACS patients with multivessel 
disease
We followed NSTE-ACS multivessel coronary artery disease (MVCAD) patients consecu-
tively admitted to our hospital from 2012 to 2015 and undergone revascularization with high-
risk PCI + ECMO support or CABG. The study included 53 patients (PCI + ECMO, n = 23, and 
CABG, n = 30). It was a single-center registry, which compared 12-month outcomes. Inclusion 
criteria were significant multivessel coronary disease and/or stenosis of the left main coronary 
artery (LMCA) ≥50%. The PCI + ECMO group of NSTE-ACS patients had an intermediate 
risk of adverse cardiovascular outcomes (mean GRACE score 117.3 ± 19.4, mean EuroScore II 
4.3 ± 3.9%), and a high SYNTAX Score: 33.3 ± 8.3. Significant LMCA stenosis was diagnosed 
in 60.7% of patients. Every third patient had diabetes mellitus, a prior myocardial infarction 
was observed in 56.4% cases, peripheral artery disease was diagnosed in 60.7% of patients 
of the study population. High-risk PCI was defined as having two of the three parameters: 
(1) left ventricular ejection fraction less than 35%; (2) a large amount of myocardium at risk 
(Jeopardy Score 8 and more [2]) and (3) complex PCI. An indication for high-risk PCI with 
ECMO support was based on the heart team decision for those patients, who were not suit-
able for some types of revascularization (CABG or PCI) and who had two of the three param-
eters of high-risk PCI.
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The CABG group patients also had a moderate risk of adverse cardiovascular outcomes (mean 
GRACE score 97.5 ± 15.0, mean EuroScore II 2.7 ± 2.1%), and an intermediate-high SYNTAX 
Score: 29.7 ± 8.3. Significant LMCA stenosis was diagnosed in 36.6% of patients. Diabetes mel-
litus was present in 16.6% of patients, 60% of patients had a prior myocardial infarction and 
in every third patient of the study population, peripheral artery disease was diagnosed. Thus, 
there were no statistically significant differences between the groups in terms of the baseline 
clinical characteristics, but the PCI + ECMO group had a potentially slightly poorer prognosis 
compared with the CABG group (Table 3).
In order to perform PCI + ECMO, we used 21–23 Fr venous cannula for the right common fem-
oral vein with a surgical technique. For the iliac artery—17-18 Fr arterial cannula was used. 
The mean ECMO flow was about 2.5 L/min/m2 with a duration of 95.4 ± 25.2 min. During PCI 
all patients received unfractionated heparin, and acetylsalicylic acid before PCI. About 42%of 
patients received the loading dose of clopidogrel before PCI. After the surgical cannulation 
wound closure, the remaining patients received the loading dose of clopidogrel. We con-
nected ECMO (“RotaFlow System” developed by the MAQUET Getinge Groupe, Hirrlingen, 
Germany) before the start of PCI.
The patients in both groups were waiting for revascularization for about 2 weeks. About 
89.9% of the CABG patients had complete revascularization. There were significantly fewer 
patients having had complete revascularization in the PCI + ECMO group: 30.3% (p = 0.0001). 
Variables PCI + ECMO (n = 23) CABG (n = 30) Р
Mean age 67.5 ± 8.5 (48–82) 64.4 ± 7
(45–75)
0.125
Male 15 (65.2%) 19 (63.3%) 0.9
Mean left ventricular ejection fraction 47.5 ± 12.8% 54.4 ± 10.0% 0.069
Left ventricular ejection fraction ≤40% 9 (39%) 1 (3.3%) 0.001
Mean GRACE SCORE 117.3 ± 19.4 97.5 ± 15.0 0.205
LMCA stenosis ≥50% 14 (60.7%) 11 (36.6%) 0.08
Diabetes mellitus 8 (34.7%) 5 (16.6%) 0.13
Prior myocardial infarction 13 (56.4%) 18 (60%) 0.8
Arterial hypertension 22 (95.4%) 27 (89.9%) 0.5
Peripheral artery disease 14 (60.7%) 11 (33.3%) 0.049
Prior stroke 2 (8.6%) 2 (6.6%) 0.8
EuroScore II 4.3 ± 3.9% 2.7 ± 2.1 0.01
SYNTAX Score 33.3 ± 8.3 29.7 ± 8.3 0.062
Jeopardy score 10.6 ± 1.8 10.6 ± 1.7 0.876
Table 3. Baseline characteristics of the study groups.
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Implanted stents mean length and diameter were 54.6 ± 25.3 mm and 3.28 ± 0.4 mm, respec-
tively. During the PCI procedure, 2.8 ± 1.1 DES were implanted. The average number of grafts 
in the CABG group was 2.8 ± 0.6.
The study endpoints included death, myocardial infarction, stroke, repeated unplanned 
revascularization and the combined endpoint of death, myocardial infarction, stroke, and 
revascularization.
It is important to note, that the in-hospital mortality in the PCI + ECMO group was 4.3% and 
the combined endpoint of adverse events (MACE) (death, MI, stroke, repeated revasculariza-
tion) was 8.7%. We observed a high rate of significant hemorrhagic complications (BARC 3) 
caused by the use of the ECMO cannula: up to 47.8%. Despite this, after 12 months of follow-
up, mortality and MACE increased only to 8.7 and 17.4%, respectively. Repeated revascular-
ization was required only in 1 (4.3%) case. These results make it clear that the revascularization 
approach is justified when PCI is performed on severe stenotic lesions in the large proximal 
parts of the coronary arteries that supply significant areas of the viable myocardium.
The in-hospital results in the CABG group were characterized by a high mortality level 
(9.99%). MACE in the hospital period reached 13.3%. Significant hemorrhagic complications 
(BARC 3–4) occurred in 26.6% of cases, which was the expected outcome in the group of open 
surgical treatment. Mortality and MACE in the CABG group increased to 13.3 and 23.3%, 
respectively, after 12 months of follow-up. The analysis of the results shows a high propor-
tion of in-hospital and long-term adverse events, which is caused by a high risk of the open 
surgery in NSTE-ACS MVCAD patients with a high SYNTAX score. These results should not 
be considered as unfavorable because according to the data of our Registry [25], the prognosis 
in this group of patients was extremely poor in the absence of revascularization (mortality 
rate reached 28%).
The comparison of the PCI + ECMO and CABG results of in NSTE-ACS MVCAD patients 
showed no significant differences in the study endpoints at 12-month follow-up (Table 4) 
despite a potentially poorer prognosis in the PCI + ECMO group compare to the CABG group 
based on baseline clinical characteristics.
Thus, PCI + ECMO may be an alternative to the CABG revascularization strategy for NSTE-
ACS MVCAD patients with a high surgical risk. Although CABG remains the conventional 
Variables PCI + ECMO (n = 23) CABG (n = 30) Р
Death 2 (8.7%) 4 (13.3%) 0.27
Myocardial infarction 2 (8.7%) 2 (6.6%) 0.77
Stroke 1 (4.3%) 0 0.26
Revascularization (unplanned) 1 (4.3%) 2 (6.6%) 0.7
MACE (death, MI, stroke, repeated revascularization) 4 (17.4) 7 (23.3%) 0.6
Table 4. Twelve-month outcomes of various treatment strategies.
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method of revascularization for patients with complex coronary disease including multives-
sel and LMCA disease, PCI + ECMO is a technique that improves the access to revasculariza-
tion for high-risk patients who are often refused a CABG surgery.
In our study, we included patients with a high risk of adverse outcomes for any type of revas-
cularization (CABG and PCI). We assume that PCI + ECMO is a possible strategy of revas-
cularization for high-risk NSTE-ACS patients. These patients usually have diffuse coronary 
artery disease involving LMCA. PCI with ECMO support makes it possible to perform a suc-
cessful revascularization with no hemodynamic instability.
The present study had several limitations. First of all, it was not randomized. A very criti-
cal clinical and angiographic status of the PCI patient group gave us the opportunity to test 
ECMO as a method of PCI support in a high-risk cohort of NSTE-ACS patients. It is necessary 
to conduct randomized trials to answer the question on the role of ECMO support for high-
risk PCI in NSTE-ACS patients.
4. Conclusions
Currently, the guidelines approve the use of ECMO support in cardiogenic shock or cardiac 
arrest patients. There are limited data on the use of ECMO support for PCI in stable angina 
and NSTE-ACS patients without hemodynamic disturbances. However, the use of ECMO 
for PCI support has a theoretical and practical rationale and showed encouraging results 
in our single-center observation. Our single-center experience demonstrated that PCI sup-
ported by ECMO may be an alternative for high-risk revascularization (CABG and PCI) 
for both stable angina and NSTE-ACS patients. The extremely poor prognosis in high-risk 
patients treated with a pharmacological approach who are often refused a CABG surgery 
or standard PCI makes PCI + ECMO method very promising as it improves the access to 
revascularization.
Our experience in this study allowed us to come to the following conclusions. A detailed 
assessment of the viable myocardium in a group of patients with stable coronary artery 
disease can improve the 12-month results as a more accurate selection of patients for 
PCI + ECMO support will be done. A particular attention should be paid to factors that 
increase the probability of stent thrombosis. The role of this revascularization method for 
NSTE-ACS patients is more obvious. PCI + ECMO is a life-saving technique that significantly 
improves hospital and 12-month survival of patients who were refused a CABG surgery or 
standard PCI. Unfortunately, we do not know the exact indications for ECMO in the elective 
pre-procedural setting, therefore, we need to develop a methodology (calculator) to imme-
diately assess the need for mechanical circulatory support devices during high-risk PCI. In 
the end, selection of mechanical circulatory support devices is a matter of a personalized 
approach and should be based on the results of upcoming large randomized comparative 
studies.
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